Evolent Health(US:EVH)2025-05-08 20:17Financial Performance - Revenue for Q1 2025 was $483.6 million, exceeding expectations, but declined by $156 million compared to Q1 2024 due to previously disclosed contracting changes[6] - Adjusted EBITDA for Q1 2025 was $36.9 million, at the high end of expectations, driven by strong execution across all lines of business[6] - The company had $246.5 million in cash and cash equivalents as of March 31, 2025, after generating $4.6 million in cash flow from operations in the quarter[6] - The company drew $200.0 million on its Term Facility and repaid $37.5 million on its Revolving Facility, resulting in a net increase in debt of $162.5 million in Q1 2025[6] - Net Debt to LTM Adjusted EBITDA was 4.1x, with LTM Adjusted EBITDA of $143.2 million[6] Strategic Initiatives and Outlook - The company announced five new revenue agreements, anticipated to contribute approximately $10 million in incremental annualized revenue[6] - The company officially launched the Oncology Navigation Solution within integrated Oncology Condition Management, expecting it to be available to over 300,000 members by the end of May[6] - The company reiterated its full-year 2025 revenue guidance of $2.06 billion to $2.11 billion and Adjusted EBITDA guidance of $135 million to $165 million[7] - The company lowered its Q2 2025 revenue outlook to $440 million - $470 million due to capitation rate true-ups for 2024 launches in Performance Suite, with no impact on bottom line outlook[7] Operational Metrics - Average lives on the Performance Suite platform were 6,486,000 in Q1 2025[12] - Average lives on the Specialty Technology and Services Suite platform were 77,079,000 in Q1 2025[12] - Performance Suite Average PMPM fee was $15.57 in Q1 2025[12]